What is Porton Advanced?
Founded in 2018 and headquartered in Suzhou, Jiangsu, China, Porton Advanced operates as a sophisticated therapy development platform provider. The company specializes in providing end-to-end solutions for the development and manufacturing of advanced therapies, including cell and gene therapies. By integrating complex technical expertise with a scalable service model, Porton Advanced addresses the critical bottlenecks often faced by biotech firms during the transition from clinical research to commercial-scale production. Its market position is defined by its ability to bridge the gap between laboratory-scale innovation and industrial-grade manufacturing, making it an essential partner for pharmaceutical companies navigating the complexities of modern medicine.
How much funding has Porton Advanced raised?
Porton Advanced has raised a total of $80M across 1 funding round:
Series B
$80M
Series B (2022): $80M with participation from China Merchants Capital, SDICTK, Fosun Health Capital, Merchant Health, and Gortune Investment
Key Investors in Porton Advanced
China Merchants Capital
An alternative asset management firm backed by China Merchants Group and GLP, focusing on diverse sectors including healthcare, advanced manufacturing, and infrastructure.
Fosun Health Capital
A specialized investment arm of the Fosun Group, dedicated to identifying and scaling high-potential opportunities within the global healthcare and life sciences industry.
Gortune Investment
A professional investment institution focused on long-term value creation through strategic capital allocation in emerging technology and healthcare sectors.
What's next for Porton Advanced?
With the successful closure of this latest funding round, Porton Advanced is well-positioned to execute its next phase of strategic expansion. The company is expected to prioritize the enhancement of its manufacturing facilities and the expansion of its technical workforce to meet the rising demand for high-quality therapy development services. Furthermore, the infusion of capital will likely facilitate deeper investments in R&D, allowing the firm to refine its platform capabilities and potentially enter new therapeutic verticals. As the biotech sector continues to evolve, Porton Advanced's focus on operational excellence and strategic partnerships will be pivotal in sustaining its growth and maintaining its competitive edge in the global healthcare ecosystem.
See full Porton Advanced company page
